Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expressing Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Early research (Phase 1)UnknownNCT06254807
What this trial is testing

CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positive
Carisma Therapeutics Inc 6
Early research (Phase 1)Not Yet RecruitingNCT07036185
What this trial is testing

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Who this might be right for
Gastric/Gastroesophageal Junction CancerBreast CancerColorectal Cancer+3 more
Shanghai Bao Pharmaceuticals Co., Ltd. 66
Early research (Phase 1)Not Yet RecruitingNCT05320874
What this trial is testing

KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Who this might be right for
Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd. 232
Early research (Phase 1)Study completedNCT00084513
What this trial is testing

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Fox Chase Cancer Center 18
Early research (Phase 1)Study completedNCT04257110
What this trial is testing

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Who this might be right for
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd 117
Testing effectiveness (Phase 2)UnknownNCT05805956
What this trial is testing

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Who this might be right for
Advanced Solid TumorAdvanced Lung CancerAdvanced Gastric Carcinoma+1 more
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 105
Early research (Phase 1)Active Not RecruitingNCT05311397
What this trial is testing

A166 in Patients With Advanced Solid Malignant Tumors

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 120
Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Early research (Phase 1)UnknownNCT05145179
What this trial is testing

Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Who this might be right for
Receptor, ErbB-2
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 162
Testing effectiveness (Phase 2)Study completedNCT02386501
What this trial is testing

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Who this might be right for
HER2 Expressing Solid Tumors
Advaxis, Inc. 12
Testing effectiveness (Phase 2)Ended earlyNCT06516926
What this trial is testing

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Who this might be right for
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 11
Testing effectiveness (Phase 2)Looking for participantsNCT07192432
What this trial is testing

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Who this might be right for
HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc. 27
Testing effectiveness (Phase 2)Looking for participantsNCT07646626
What this trial is testing

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD. 150
Early research (Phase 1)Study completedNCT04162327
What this trial is testing

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Who this might be right for
Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 55
Testing effectiveness (Phase 2)UnknownNCT05349409
What this trial is testing

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Who this might be right for
Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 212
Early research (Phase 1)Study completedNCT04235101
What this trial is testing

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Who this might be right for
Solid Tumor
Byondis B.V. 32
Testing effectiveness (Phase 2)Looking for participantsNCT07022002
What this trial is testing

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Who this might be right for
Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD. 340
Testing effectiveness (Phase 2)Looking for participantsNCT07512583
What this trial is testing

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 178
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Next Page